Strategies to augment immunity to self/neoantigens expressed by cancers are urgently
needed to expand the proportion of patients benefiting from immunotherapy, particularly for …

Heterologous prime-boost immunization with plasmid DNA and viral vector vaccines is an
emerging approach to elicit CD8+ T cell–mediated immunity targeting pathogens and tumor …

Autologous cancer vaccines (ACVs) are a desirable approach for personalized medicine,
but the efficiency of ACVs remains unsatisfactory due to their low immunogenicity. This study …

Therapeutic neoantigen cancer vaccines have limited clinical efficacy to date. Here, we
identify a heterologous prime-boost vaccination strategy using a self-assembling peptide …

Progressive tumor growth is associated with deficits in the immunity generated against tumor
antigens. Vaccines targeting tumor neoepitopes have the potential to address qualitative …

After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

Background Antitumor therapeutic vaccines are generally based on antigenic epitopes
presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific …

Recent advances in several areas are rekindling interest and enabling progress in the
development of therapeutic cancer vaccines. These advances have been made in target …

Background Immunization with tumor neoantigens is a promising vaccine approach to
promote antitumor immunity due to their high immunogenicity, lack of expression in normal …

Background Aberrant sialoglycans on the surface of tumor cells shield potential tumor
antigen epitopes, escape recognition, and suppress activation of immunocytes. α2, 3/α2 …